Skip to content
Study details
Enrolling now

A Study to Assess NAV-240 in Adult Participants With Hidradenitis Suppurativa

Navigator Medicines, Inc.
NCT IDNCT07384975ClinicalTrials.gov data as of Apr 2026
Phase

Phase 2

Ages

18–70

Locations

10 sites in AZ, FL, KY +2

About this study

This Phase 2 study is focused on people with hidradenitis suppurativa.

Based on ClinicalTrials.gov records.

PhasePhase 2

Participation effort

Estimated from trial records. Details can vary by site.

Time + visits
Low12%
Logistics
Moderate50%

Logistics difficulty varies by site location and availability.

Trial highlights

Treatment details

Auto-extracted from trial records to preview treatments and outcomes.

Endpoints

Secondary: Change from baseline in AN count, Change from baseline in the number of draining tunnels, Proportion of participants achieving skin pain numeric rating scale (NRS) 30 response